Management of obesity

Efficacy of phentermine/topiramate extended release in weight management and metabolic profiles: A multicentre study in South Korea

AIMS

Clinical trials have demonstrated the effectiveness of the phentermine and topiramate combination in weight management. This research evaluated the efficacy and safety of phentermine/topiramate extended release (ER) for weight management, focusing on alterations in body weight and metabolic parameters in routine clinical practice.

MATERIALS AND METHODS

We retrospectively included people with obesity who initiated phentermine/topiramate ER between January 2020 and April 2023 at 10 tertiary hospitals in South Korea. The study assessed body weight changes at 5-6 months and for those who continued, at 12 months, along with metabolic parameters. Total body weight was measured using calibrated electronic scales with participants in light indoor clothing.

RESULTS

The cohort included 1839 patients (540 men and 1299 women), with a 5-6-month continuation rate of 48%. At 5-6 months, the mean weight reduction was 7.9%, with sex-specific losses of 7.1% in men and 8.2% in women. Over 56% of participants achieved more than 5% weight loss, with 23% exceeding a 10% reduction. Younger participants, women and those with moderate to severe obesity exhibited more pronounced weight loss compared to older men and individuals with mild obesity, respectively. Concurrently, phentermine/topiramate ER treatment improved glucose regulation, lipid profiles and decreased blood pressure: the HbA1c decreased by 0.4 ± 0.9%, low-density lipoprotein (LDL) cholesterol by 10 ± 32 mg/dL and systolic blood pressure by 6 ± 15 mmHg (all p < 0.001). Treatment was well-tolerated, with a 15% incidence of mild adverse events like paresthesia, dry mouth and insomnia. At 12 months, patients who persisted in treatment (21%) experienced an average weight loss of 9.6%, with 65% surpassing a 5% weight loss.

CONCLUSION

The study suggests phentermine/topiramate ER is an effective option for obesity management in a South Korean population, though long-term adherence remains a challenge.

Comparison of Different Intermittent Fasting Patterns or Different Extents of Calorie Restriction for Weight Loss and Metabolic Improvement in Adults: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

CONTEXT

Continuous energy restriction (CER) and intermittent fasting (IF) are both prevalent diet regimens recommended for weight loss and metabolic improvement.

OBJECTIVE

The objective of this study was to evaluate the efficacy of CER and IF on weight loss and metabolic improvement in adults with overweight, obesity, or metabolic abnormalities.

DATA SOURCES

PubMed, Embase, and the Cochrane Library (CENTRAL) were searched for randomized controlled trials of 3 degrees of CER diet regimens and 4 categories of IF diet regimens, from inception of the databases to December 2022.

DATA EXTRACTION

Two reviewers independently extracted demographic information, the intervention duration, details of the dietary interventions, and data on the outcomes of interest.

DATA ANALYSIS

Bayesian random-effect network meta-analyses were used to pool the results and the Grading of Recommendations, Assessment, Development, and Evaluation framework was used to assess the certainty of the evidence and to present the findings.

RESULTS

The study included 167 eligible trials with a total enrollment of 11 998 participants. Most IF diet regimens induced significant weight loss that was comparable with that induced by CER diet regimens with a similar absolute energy restriction, based on low- to high-certainty evidence. Severe CER proved to be the most effective regimen for obtaining weight loss, based on moderate-certainty evidence (mean difference of weight change 11.50 kg [95% CI 10.07 to 12.93]), followed by alternate-day fasting, based on high-certainty evidence (mean difference of weight change (5.07 kg [95% CI 3.44 to 6.72]) and moderate CER, based on moderate-certainty evidence (6.09 kg [95% CI 5.26 to 6.93]), when the regimens being compared were consistent in their absolute energy restriction extent. Similar results were noticed for body measurements, blood pressure, blood lipids, and glycemic profiles. In the subgroup analysis, the weight-loss effects of the IF but not the CER diet regimens experienced rebound after 12 weeks.

CONCLUSION

In adults with overweight, obesity, or metabolic abnormalities, effectiveness in weight loss mainly depends on the extent of the energy restriction, regardless of the mealtime patterns.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO registration no. CRD42022379621.

Effect of semaglutide with obesity or overweight individuals without diabetes: an Umbrella review of systematic reviews

OBJECTIVE

Summarize the effectiveness and safety of Semaglutide for non-diabetic obese patients through umbrella analysis.

METHODS

From inception to May 2024, we searched PubMed, EMbase, Web of Science, and The Cochrane Library for a systematic review and meta-analysis of semaglutide in non-diabetic obesity. AMSTAR-2 assessed review quality, ROB scrutinized RCT quality, and RCTs were selected based on overlap. Random-effects meta-analysis synthesized data on weight, waist, BMI, ect.

RESULTS

The study encompassed 7 reviews and 10 RCTs, revealing that semaglutide induced average weight loss 11.71 kg [-13.16, -10.26] in non-diabetic obese patients, a 12.79% reduction [-14.4, -11.18]. Notably, ≥5, ≥10, ≥15, and ≥20% weight-loss rates significantly increased. Semaglutide also reduced waist by 9.39 cm [-10, -8.79], BMI by 4.27 kg/m^2 [-4.78, -3.75], SBP by 4.78 mmHg [-5.63, -3.93], DBP by 2.56 mmHg [-3.96, -1.17], and lipids by 3.2 mmol/l [-5.65, -0.75]. FBG significantly dropped by 5.46 mmol/l [-8.99, -1.93], and SF-36 scores improved by 1.7 points [0.78, 2.63]. However, common adverse reactions included nausea [RR: 2.59], diarrhea [RR: 1.77], and constipation [RR: 2.07].

CONCLUSIONS

Semaglutide shows significant weight loss and health benefits in non-diabetic obesity. However, Recent studies show semaglutide can cause NAION and erectile dysfunction, beyond previously reported adverse reactions. Besides, High overlap in current research highlights a lack of RCTs. And there is a high degree of heterogeneity across included studies. More large-scale, rigorous RCTs are needed to assess safety and support clinical use.

REGISTER

The study was registered at PROSPERO on 24 December 2023 (registration number:CRD42023493235).

Systematic Review and Meta-analysis of Randomized Clinical Trials Comparing Time-Restricted Eating With and Without Caloric Restriction for Weight Loss

CONTEXT

Although it is well established that caloric restriction (CR) is the primary driver of weight loss, circadian-driven metabolic benefits have been recognized as possibly enhancing the effects of CR. Time-restricted eating (TRE) has emerged as a promising approach in this context.

OBJECTIVE

We conducted a systematic review and meta-analysis to compare the effects of TRE with isocaloric diet controls (analysis 1) and non-isocaloric controls (analysis 2) on anthropometric and body-composition parameters in adults with overweight or obesity.

DATA SOURCES

A search was carried out in the Medline, LILACS, Embase, and CENTRAL databases using Medical Subject Heading (MeSH) and similar terms such as "Obesity," "Obesity, Abdominal," "Time-restricted eating," "Body weight," "Changes in body weight," and others.

DATA EXTRACTION

We included 30 studies involving a total of 1341 participants. Studies were screened based on titles and abstracts followed by full-text reading, and data were extracted from eligible studies using a pre-established form. All these steps were performed by 2 authors independently and blinded, with discrepancies resolved by a third author.

DATA ANALYSIS

The results of main findings revealed that, in studies using non-isocaloric controls, the TRE group showed significant reductions in body weight (BW) (mean difference [MD]: -2.82 kg; 95% CI: -3.49, -2.15), fat mass (FM) (MD: -1.36 kg; 95% CI: -2.09, -0.63), and fat-free mass (FFM) (MD: -0.86 kg; 95% CI: -1.23, -0.49). In studies that used isocaloric control strategies, the TRE group showed significant reductions in BW (MD: -1.46 kg; 95% CI: -2.65, -0.26), FM (MD: -1.50 kg; 95% CI: -2.77, -0.24), and FFM (MD: -0.41 kg; 95% CI: -0.79, -0. 03).

CONCLUSION

TRE yields favorable anthropometric and clinical outcomes, even when intake is isocaloric between the intervention and control groups. This result suggests that circadian effects may enhance the impact of CR on excess weight.

SYSTEMATIC REVIEW REGISTRATION

PROSPERO registration no. CRD42022301594.

Comparative efficacy of different exercise types on body composition in university students: a systematic review and meta-analysis of randomized controlled trials

Background

To systematically assess the impact of various exercise modalities and dosages on the body composition of college students through a comprehensive review of randomized controlled trials (RCTs).

Methods

We conducted a comprehensive search of relevant randomized controlled trials (RCTs) in eight databases, covering data from the inception of each database to August 2024. Following the literature screening, two investigators independently conducted data extraction and assessed the risk of bias. Network meta-analysis (NMA) was conducted using Stata 17.0 with random-effects modeling, while dose-response analysis was performed utilizing R version 4.3.1.

Results

A total of 43 randomized controlled trials (RCTs), encompassing 3,154 participants, were included in the analysis. Aerobic exercise, combined exercise, high-intensity interval training (HIIT), mind-body exercise, and calisthenics demonstrated significant effects on reducing body mass index (BMI) compared to control groups. Surface under the cumulative ranking (SUCRA) probability rankings indicated that calisthenics had the highest likelihood of being the most effective intervention for BMI reduction, whereas resistance exercise was associated with the lowest likelihood. The dose-response analysis revealed that the threshold exercise dose for overall exercise to lower BMI was 310 METs-min/week, with the predicted maximum significant response dose being 1,300 METs-min/week, beyond which there was minimal change in the intervention effect. Additionally, distinct nonlinear dose-response relationships were observed for aerobic exercise, combined exercise, HIIT, mind-body exercise, and aerobics.

Conclusion

No significant differences in the effectiveness of exercise interventions on body composition were observed across exercise types. However, based on the SUCRA analysis, calisthenics emerged as the preferred intervention, succeeded by a combination of exercises. The optimal exercise dosage for enhancing body composition was identified as 1,300 METs-min/week, with the threshold for a significant effect being relatively low.

Systematic Review Registration

https://www.crd.york.ac.uk/PROSPERO/view/CRD42024587032.

Teratogenic risks of treated and untreated maternal obesity

Untreated obesity in pregnancy is associated with adverse fetal and neonatal outcomes that influence the long-term offspring health trajectory, propagating obesity and cardiometabolic disease from one generation to the next. The current efforts to reduce the risk of these negative outcomes through preconception weight loss remain largely ineffective. Anti-obesity medications (AOMs) are an understudied option for this indication, likely due to the potential for teratogenicity with accidental exposure during pregnancy. However, the current recommendation to discontinue all AOMs prior to conception fails to frame obesity within the chronic disease paradigm typically used for preconception counseling. Evolving evidence suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs), the newest and most effective AOM class, may be safe in early pregnancy. Although further research is needed, counseling about GLP-1 RAs during pregnancy should include the potential for both risk and benefit. This review summarizes the known risks that obesity in pregnancy poses to the offspring and discusses the benefits and limitations of current treatment strategies. While there remain several barriers to optimal preconception and prenatal care for people with obesity, this review aims to arm providers with the knowledge needed for patient-centered counseling prior to and during pregnancy.

Intraoperative and Postoperative Complications Rate Following Elective Pelvic Reconstructive Surgery in Women with Severe Obesity: A Retrospective Cohort Study

INTRODUCTION AND HYPOTHESIS

To assess early intraoperative and postoperative complications and outcomes in patients with severe obesity undergoing apical prolapse repair compared with patients with normal weight.

METHODS

This retrospective cohort study included 315 patients who underwent apical prolapse repair at a tertiary medical center between 2009 and 2024. Fifty-six patients had a BMI greater than 40, and 259 had a normal BMI (18.5-30). Patients with class I and II obesity were excluded from the study. Preoperative data, surgical details, and 30-day postoperative complications were collected and analyzed.

RESULTS

The average age of the patients with severe obesity was significantly lower than that of patients with normal weight (56.6 vs 64.1 years, p < 0.001). Patients with severe obesity had a higher prevalence of diabetes (27.3% vs 9.0%, p < 0.001), hypertension (54.5% vs 25.1%, p < 0.001), and obstructive sleep apnea (21.8% vs 7.4%, p = 0.001). Intraoperatively, the group with severe obesity experienced greater estimated blood loss (233.6 ml vs 115.2 ml, p < 0.001) and were more likely to undergo concurrent incontinence procedures (76.4% vs 51.3%, p = 0.001). However, no significant difference in intraoperative complications was observed between the groups (5.4% vs 5.4%, p = 1.000). Hospitalization duration was longer in patients with morbid obesity. Total complication rate within 30 days was 7.3%, with no statistically significant difference between the groups with severe obesity and normal weight.

CONCLUSION

Patients with severe obesity undergoing vaginal apical prolapse repair have similar rates of early postoperative complications and health care encounters to patients with normal weight. These findings support offering prolapse surgery to patients with morbid obesity when clinically indicated.

[Surgical treatment for obesity - metabolic surgery]

BACKGROUND

Over the past 20 years, surgical treatment of obesity, or metabolic surgery, has established itself as an extremely efficient and sustainable therapy for treating severely overweight patients. Compared to non-surgical weight reduction procedures, surgical techniques have been shown to be superior in all studies, both in terms of short-term and long-term effectiveness. On the other hand, the invasiveness of the procedures is something that many patients view critically.

PROCEDURES

Many years of experience with the two most commonly used procedures, laparoscopic sleeve gastrectomy and minimally invasive gastric bypass, show that both procedures are associated with very low morbidity. The comparatively high costs of the surgical procedure are more than offset by the long-term savings in other therapeutic needs (diabetes mellitus, hepatic steatosis, arthritis, osteoarthritis, etc.). The S3 guideline for carrying out metabolic surgical procedures has clear specifications for the criteria to be met. Embedding in a multi-modal concept both pre- and post-operatively is obligatory. The following article provides an overview of the indications, treatment, and aftercare in the field of metabolic surgery.

The influence of preoperative fat distribution on post-bariatric surgery body mass index and body weight loss

BACKGROUND

The body weight following bariatric surgery is a primary concern for both healthcare professionals and surgical candidates. However, it remains unclear whether variations in preoperative fat distribution influence weight loss outcomes.

OBJECTIVE

The aim of this study was to evaluate the effect of abdominal fat distribution on postoperative weight loss and body mass index (BMI) reduction, and to clarify the role of different fat depots in weight loss outcomes.

METHODS

Preoperative data from patients with overweight or obesity, along with their weight records at 1, 2 and 5 years following surgery, were retrospectively collected. Multiple levels of abdominal fat areas were measured using computerized tomography imaging. Statistical analyses included Pearson's correlation coefficients, multiple linear regressions, ridge regressions, decision tree regressions and paired t tests to evaluate the associations and influences.

RESULTS

A total of 139 patients were initially included. The statistical analysis results indicated that umbilical subcutaneous adipose tissue (SAT) was an independent factor influencing weight and BMI loss at the 1-year follow-up (n = 67, p < 0.01). Furthermore, umbilical SAT demonstrated significant correlations with sustained BMI reduction over the long term.

CONCLUSION

Umbilical SAT is a significant factor in postoperative weight and BMI loss. Patients with greater SAT may experience more substantial weight and BMI reductions following surgery, offering new insights into personalized weight loss strategies and alternative approaches for assisted weight loss.

Investigating the Salivary Biomarker Profile in Obesity: A Systematic Review

PURPOSE OF REVIEW

This systematic review aims to map the existing literature on salivary biomarkers in adults with metabolically unhealthy obesity (MUO), identify key biomarkers associated with this high-risk group, and highlight areas requiring further research to advance this emerging field.

RECENT FINDINGS

Obesity is characterized by an abnormal accumulation of body fat and chronic inflammation. However, not all individuals with obesity experience metabolic dysfunction. This review focuses on MUO, which is strongly linked to metabolic disorders such as insulin resistance, cardiovascular disease, type 2 diabetes, and systemic inflammation. Linking MUO and salivary biomarkers may enhance our understanding of how systemic health influences salivary composition and could enable the early identification of high-risk individuals through non-invasive saliva testing. This review synthesized findings from recent studies and identified key salivary biomarkers consistently elevated in individuals with MUO, including 8-OHdG, IL-6, IL-8, resistin, TNFR1, PTX-3, AEA, OEA, TNF-α, and sICAM-1. These biomarkers are associated with inflammation, oxidative stress, and metabolic dysregulation. The majority of studies utilized cross-sectional designs and used various saliva collection methods. Salivary biomarkers hold promise as non-invasive indicators of obesity-related metabolic dysfunction, particularly in MUO. However, their clinical diagnostic utility remains uncertain due to heterogeneity in study designs, a lack of biomarker validation, and limited longitudinal studies. Further research is needed to establish their bona fide diagnostic potential.

ENERGY expenditure of COmmuting to school (ENERGYCO): protocol for a cluster randomized controlled trial

Introduction

This article outlines the rationale and methodology of the ENERGY expenditure of COmmuting to school study (the ENERGYCO study), a cluster-randomized controlled trial. The ENERGYCO study is divided into two phases: Phase I will aim; to assess the physical activity energy expenditure (PAEE) of different modes of commuting to school (i.e., walking, cycling, and motorized-vehicle) using indirect calorimetry in Spanish adolescents; and Phase II will aim to assess the effect of a school-based cycling intervention on resting metabolic rate and PAEE, as well as on other physiological, physical, and psychosocial outcomes on Spanish adolescents.

Method

For Phase I, a convenience sample of ~50 adolescents will be recruited. These participants will have their PAEE assessed in three different modes of commuting. Regarding phase II, a total of 300 adolescents from different schools in three Spanish cities will participate in this cluster randomized controlled trial. As many schools as necessary to meet the target sample will be included. In addition, each school will be randomized as either an intervention or control group. Participants from intervention schools will be asked to complete a school-based cycling intervention, while participants from control schools will be asked to continue their same habits for 8 weeks. The school-based cycling intervention will last for 8 weeks and will include Bikeability sessions, along with encouragement strategies to increase adherence to cycling to and from school.

Conclusion

The ENERGYCO study will provide novel insights into the PAEE associated with different modes of commuting to school using indirect calorimetry, as well as a comprehensive overview of how an 8-week school-based cycling intervention impacts resting energy expenditure, daily energy expenditure, and the physical and psychosocial health of adolescents.

Effects of semaglutide in patients with chronic ankle instability: evidence from a prospective cohort

BACKGROUND

Whether patients with chronic ankle instability (CAI) can benefit from weight loss yielded by using glucagon-like peptide-1 receptor agonists (GLP1-RAs) has remained unclear.

METHODS

In this observational study, we recruited more than 2000 adults with CAI according to the selection criteria proposed by International Ankle Consortium with at least two-year follow up from three medical centers. The primary endpoint was the change from baseline of the Foot and Ankle Ability Measure (FAAM) sports subscale at the last follow up. Secondary endpoints included the change from baseline of Foot and Ankle Outcome Score (FAOS)/ Cumberland Ankle Instability Tool (CAIT)/ FAAM activities of daily living (ADL) subscale, number of ankle sprains during study period, incident ankle surgery in treatment of CAI.

RESULTS

In this study, 71 out of 2018 patients who received semaglutide in purpose of treating type 2 diabetes (T2DM) and/or weight loss during the study period. After controlling baseline characteristics, the adjusted mean difference in change from baseline was 16.3 for FAAM sports subscale and 9.3 for FAAM ADL subscale. Likewise, the adjusted analysis of five subscales of FAOS showed similar results, all consistently favoring semaglutide group. For CAIT, patients in the semaglutide group had achieved statistically significant improvement compared with control group. The association of semaglutide exposure with improvement in FAAM sports and ADL subscales was mediated by the weight loss measured by BMI (mediation proportion: FAAM sports subscale, 31.2% [22.2-41.2%]; FHSQ ADL subscale, 34.1% [24.4-44.8%]). We also observed statistically significant decreases in number of recurrent ankle sprains during study period. For incident ankle surgery, 1 out of 71 patients (1.4%) and 151 out of 1947 patients (7.8%) received ankle surgeries in semaglutide and control groups, respectively (P = 0.047).

CONCLUSIONS

Semaglutide may show potential benefits as a supplementary intervention in treatment of CAI by improving patient-reported outcomes and preventing recurrent ankle sprains. Further randomized trial is warranted by the current study to further confirm our findings.

TRIAL REGISTRATION

researchregistry10716.

Association of long-term weight management pharmacotherapy with multiple health outcomes: an umbrella review and evidence map

BACKGROUND

Multiple meta-analyses (MAs) have demonstrated that six pharmacotherapies, including orlistat, liraglutide, phentermine/topiramate, naltrexone/bupropion, semaglutide, and tirzepatide, improve weight loss and weight maintenance. However, few studies have synthesized and evaluated the quality of this evidence.

OBJECTIVE

To identify the relevant MAs of randomized clinical trials (RCTs) that explored the association between the six pharmacotherapies and obesity-related health outcomes and adverse events (AEs).

METHODS

A comprehensive search was conducted across PubMed, Embase, Cochrane Library, and Web of Science from database inception up to January 2024. We calculated the effect size as the mean difference and risk ratio using the random-effects model. The quality of MAs was evaluated using "A Measurement Tool to Assess Systematic Reviews 2".

RESULTS

Sixteen MAs comprising 235 RCTs that described 115 unique associations between the six pharmacotherapies and various health outcomes were included. Overall, 101 statistically significant associations (88%) had beneficial outcomes on body weight, weight loss, waist circumference, body mass index, total cholesterol, triglycerides, both low-density and high-density lipoprotein cholesterol, blood pressure, and glycemic profile. The pharmacotherapies were associated with significant weight loss and partial improvements in the lipid profile, blood pressure, and glycemic control among individuals with overweight or obesity. Notable AEs were associated with liraglutide, naltrexone/bupropion, semaglutide, and orlistat. The methodological quality of the included MAs requires improvement.

CONCLUSIONS

This umbrella review identified significant beneficial associations between pharmacotherapies and anthropometric measures, lipid profile, blood pressure, glycemic profile, and quality-of-life outcomes in individuals with overweight or obesity. In addition, the umbrella review highlighted safety considerations. The findings affirm the efficacy of the six pharmacotherapies in promoting weight loss in this demographic. Further clinical trials with long-term follow-up are essential to evaluate the effects of these pharmacotherapies on clinical outcomes, including cancer, cardiovascular events, and mortality.

Effects of ketogenic and low-carbohydrate diets on the body composition of adults with overweight or obesity: A systematic review and meta-analysis of randomised controlled trials

BACKGROUND AND AIMS

More than one-third of individuals are overweight and obese in the world. Their risks of chronic health conditions are increased, which places additional burden on their family, caregivers, and healthcare system. Dietary modification is widely used for overweight and obese individuals. We investigated the effects of ketogenic diet (KD) and low-carbohydrate diet (LCD) in improving body weight (BW), body mass index (BMI), fat mass (FM), and body fat percentage (BFP) in overweight or obese individuals.

METHODS

A three-step approach was adopted for searching relevant randomised controlled trials (RCTs) across five electronic databases. Two reviewers conducted the screening, review, and quality appraisal independently. A random-effects model was used because of variations in intervention and participant characteristics. Sensitivity and subgroup analyses were conducted to assess heterogeneity and variations in the results, respectively.

RESULTS

Thirty-three RCTs involving 2821 individuals were included. Overall meta-analysis results indicated that KD/LCD significantly reduced BW, BMI, and BFP, but not FM, in individuals with a carbohydrate intake of ≤100 g/d. Subgroup analyses revealed significant improvements in BW, BMI, and FM in individuals on KD/LCD for ≥1 month and in all parameters for those with a carbohydrate intake of ≤50 g/d. High statistical heterogeneity was noted because of variations in interventions and participant characteristics.

CONCLUSION

Adults with overweight or obesity should consume KD/LCD for ≥1 month and limit carbohydrate intake to ≤50 g/d. Further multicentre or multicountry RCTs are needed to improve the generalisability of our findings. We recommend integrating text messaging and evidence-based information to support interventions and ensuring stringent medical supervision throughout the intervention.

PROSPERO REGISTRATION NUMBER

CRD42022353074.

Reallocating Time Between 24-h Movement Behaviors for Obesity Management Across the Lifespan: A Pooled Data Meta-Analysis of More Than 9800 Participants from Seven Countries

BACKGROUND

The distribution of time across physical activity, sedentary behaviors, and sleep appears to be essential for the management of obesity. However, the impact of reallocating time among these behaviors, collectively known as 24-h movement behaviors, remains underexplored.

OBJECTIVE

This study examines the theoretical effects of reallocating time between 24-h movement behaviors on obesity indicators across different age groups.

METHODS

We performed a pooled data meta-analysis of 9818 participants from 11 observational and experimental studies. To estimate the time spent in movement behaviors, we reprocessed and harmonized individual-level raw accelerometer-derived data. Isotemporal substitution models estimated theoretical changes in body mass index (BMI) and waist circumference (WC) associated with time reallocation between movement behaviors. We performed the analysis separately for children, adolescents, adults, and older adults.

RESULTS

Even minor reallocations of 10 min led to significant changes in obesity indicators, with pronounced effects observed when 30 min were reallocated. The most substantial adverse effects on BMI and WC occurred when moderate-to-vigorous physical activity (MVPA) was reallocated to other movement behaviors. For 30-min reallocations, the largest increase in BMI (or BMI z-score for children) occurred when MVPA was reallocated to light-intensity physical activity (LPA) in children (0.26 units, 95% confidence interval [CI] 0.15, 0.37) and to sedentary behavior (SB) in adults (0.72 kg/m2, 95% CI 0.47, 0.96) and older adults (0.73 kg/m2, 95% CI 0.59, 0.87). The largest increase in WC was observed when MVPA was substituted with LPA in adults (2.66 cm, 95% CI 1.42, 3.90) and with SB in older adults (2.43 cm, 95% CI 2.07, 2.79). Conversely, the highest magnitude of the decrease in obesity indicators was observed when SB was substituted with MVPA. Specifically, substituting 30 min of SB with MVPA was associated with a decrease in BMI z-score by - 0.15 units (95% CI - 0.21, - 0.10) in children and lower BMI by - 0.56 kg/m2 (95% CI - 0.74, - 0.39) in adults and by - 0.52 kg/m2 (95% CI - 0.61, - 0.43) in older adults. Reallocating time away from sleep and LPA showed several significant changes but lacked a consistent pattern. While the predicted changes in obesity indicators were generally consistent across age groups, inconsistent findings were observed in adolescents, particularly for reallocations between MVPA and other behaviors.

CONCLUSIONS

This investigation emphasizes the crucial role of MVPA in mitigating obesity risk across the lifespan, and the benefit of substituting SB with low-intensity movement behaviors. The distinct patterns observed in adolescents suggest a need for age-specific lifestyle interventions to effectively address obesity. Emphasizing manageable shifts, such as 10-min reallocations, could have significant public health implications, promoting sustainable lifestyle changes that accommodate individuals with diverse needs, including those with severe obesity.

Efficacy and safety of a novel oral hydrogel capsule in adults with overweight or obesity: the pivotal randomized RESET study

OBJECTIVE

The objective of this study was to investigate the efficacy and safety of the Epitomee capsule versus placebo as an adjunct to high-intensity lifestyle intervention in participants with overweight or obesity.

METHODS

The Randomized Evaluation of Efficacy and Safety of the Epitomee Capsule Trial (RESET) was a prospective, double-blind, placebo-controlled pivotal trial in adults with baseline BMI of 27.0 to 40.0 kg/m2. The co-primary endpoints at week 24 were percentage change from baseline in body weight for the Epitomee and placebo groups and proportion of Epitomee-treated patients achieving ≥5% weight loss compared with a 35% threshold. The primary safety endpoint was the incidence of device-related serious adverse events.

RESULTS

A total of 138 participants received Epitomee and 141 received placebo. Mean (SD) change in body weight from baseline was -6.6% (6.5%) with Epitomee and -4.6% ( 4.7%) with placebo; least-squares means were -6.1% (0.6%) and -4.2% (0.6%), respectively (p = 0.0054). Fifty-six percent of Epitomee-treated participants attained ≥5% weight loss from baseline, which was significantly greater than the 35% predefined threshold (p < 0.0001). Twenty-seven percent of Epitomee-treated and eleven percent of placebo-treated participants achieved ≥10% weight loss. Adverse event rates were similar between the groups. No device-related serious adverse events occurred.

CONCLUSIONS

The Epitomee capsule is a safe and efficacious nonpharmacological option for weight management with potential broad application in participants with overweight or obesity.

Health in Spanish older people: Dietary habits, lifestyles and related socioeconomic factors

Objective

To measure diet quality in the population aged over 65 years in Spain and its autonomous communities and to identify sociodemographic, health and lifestyle factors related to diet quality based on 2017 Spanish National Health Survey.

Methods

To estimate diet quality, we used the Healthy Eating Index for Spanish Population (IASE). A multiple linear regression analysis (regression coefficients and 95 % CIs) was used to determine the relationship between socio-demographic, health and lifestyle factors and IASE. This index was our dependent variable and as independent variables: sex, chronic diseases, age, level of education, engagement in physical activity, marital status and Body Mass Index.

Results

A total of 6325 participants were included in the sample. The diet quality rating in Spain revealed that 0.46 % of our population had an unhealthy diet, 87 % needed to make changes, and 12.3 % were following a healthy diet. Being female (Regression coefficient = 1.6, 95 % CI = 1.14;-1.97), being physically active several times a month (Regression coefficient = 1.6, 95 % CI =0.63-2.48) and several times a week (Regression coefficient = 2.2, 95 % CI =1.36-3.10), having chronic disease (Regression coefficients =0.7, 95 % CI =0.08-1.29), being overweight (Regression coefficient = 0.5, 95 % CI =0.06-0.95) and being aged between 70 and 74 (Regression coefficient = 0.5, 95 % CI =0.01-1.07) and 75-79 (Regression coefficient = 0.9, 95 % CI =0.33-1.50) were associated with higher IASE scores.

Conclusion and implications

These results help to identify risk groups or situations and to design health prevention programs.

Efficacy of dietary and lifestyle interventions in obesity management: a therapeutic protocol at the Diabetes Department, Marius Nasta Institute of Pneumophthisiology, Bucharest, Romania

The primary objective of this study was to underline the importance of comprehensive medical education in the management of obesity. In clinical practice, patients frequently encounter challenges in achieving weight-related goals. Given that obesity is a major cause of global mortality, we aimed to evaluate the effectiveness of implementing targeted educational interventions on patient outcomes. To this end, we developed a specific dietary plan and educational materials for lifestyle modification administered to 44 patients in the Diabetes Department of Marius Nasta Institute of Pneumophthisiology in Bucharest, Romania. Assessments were conducted at baseline and after a three-month intervention period. The total body weight loss was 11%. BMI reductions were reflected in the redistribution of obesity types. The number of overweight individuals increased from 10 men (22.72%) to 13 men and 5 women, totaling 18 individuals (40.90%, with 29.54% men and 11.36% women). Blood glucose values dropped by 5%, and levels of HbA1c dropped by 0.4% from baseline to follow-up. The SAS severe group went down from 16 patients to 10 patients, and there was an increase in the mild Sleep Apnea Syndrome (SAS) group, increasing from 8 to 14, resulting in a 13.63% overall increase. Our findings indicate that enhanced engagement by the therapeutic team, combined with detailed educational resources and adequate time for their comprehension, improved patient health outcomes, led to weight reduction and a reduction in the severity of comorbidities such as hypertension, dyslipidemia, and sleep apnea, which translated to improved quality of life.

The Impact of Ketogenic Nutrition on Obesity and Metabolic Health: Mechanisms and Clinical Implications

The ketogenic diet (KD) has recently gained increasing popularity. This high-fat, adequate-protein, and carbohydrate-poor eating pattern leads to nutritional ketosis. The KD has long been known for its antidiabetic and antiepileptic effects and has been used therapeutically in these contexts. Recently, the KD, due to its effectiveness in inducing weight loss, has also been proposed as a possible approach to treat obesity. Likewise, a KD is currently explored as a supporting element in the treatment of obesity-associated metabolic disorders and certain forms of cancer. Here, we discuss the metabolic and biochemical mechanisms at play during the shift of metabolism to fatty acids and fatty acid-derived ketone bodies as main fuel molecules, in the substitution of carbohydrates, in ketogenic nutrition. Different sources of ketone bodies and KDs as alternatives to glucose and carbohydrates as main energy substrates are discussed, together with an attempt to weigh the benefits and risks posed by the chronic use of a KD in the context of weight loss, and also considering the molecular effects that ketone bodies exert on metabolism and on the endocrine system.

Impact of In-Person and Mobile Exercise Coaching on Psychosocial Factors Affecting Exercise Adherence in Inactive Women With Obesity: 20-Week Randomized Controlled Trial

BACKGROUND

Regular exercise may counteract obesity-related health risks, but adherence is low among individuals with obesity. Personal trainers may positively influence exercise behavior by providing motivational support. Individuals who receive regular exercise coaching are more likely to adhere to their exercise routine, compared with those who exercise individually. However, investing in personalized exercise guidance, such as a personal trainer, can be expensive for the individual. Thus, integrating web-based coaching could be a more economically sustainable option, offering both flexibility and reduced costs compared with in-person coaching only. Yet, research is needed to assess the effect of hybrid models in improving psychosocial factors among women with obesity.

OBJECTIVE

This 20-week, pragmatic randomized controlled trial aimed to investigate the effect of weekly in-person coaching compared with 2 combinations of in-person and web-based coaching on 5 psychosocial factors in women with obesity (BMI ≥30 kg/m2).

METHODS

Participants were invited through Facebook and Instagram advertisements posted by various fitness clubs across rural and urban locations in Norway (7 different counties and 12 different municipalities). Women with low activity (n=188; <150 minutes of moderate-intensity physical activity/week; 42.7, SD 10.5 years; mean BMI of 35.1, SD 6.9 kg/m2) were allocated into 3 groups of in-person coaching-weekly (n=47), twice weekly (n=47), and once monthly (n=47)-and as controls (n=47). Those with twice weekly and once monthly in-person coaching received web-based coaching of 15 minutes during weeks without in-person coaching. Data included background variables, motivation (Behavioral Regulation in Exercise Questionnaire-2), barriers, self-efficacy (The Self-Efficacy Survey), social support (Social Support Questionnaire), and health-related quality of life (36-Item Short Form Health Survey [SF-36]).

RESULTS

A total of 120 (64%) out of 188 participants completed baseline and postintervention assessments. A minor difference was observed in one item of the SF-36, where all intervention groups reported a greater "change in health last year" than the control group (mean difference: 14.2-17.1, 95% CI 2.04-29.5; g=0.79-1.14; P≤.01). No other effects were found on the selected psychosocial factors. It should be noted that controls reported higher intrinsic motivational regulation at baseline than intervention groups (mean difference: 0.43-0.93; P≤.05). All intervention arms exercised more frequently than controls (mean difference: 1.1-1.5; P≤.001), with no differences in weekly exercise frequency between the 3 intervention arms (P=.30).

CONCLUSIONS

We found no effects on motivation, barriers, self-efficacy, perceived social support, or other health domains compared with controls. All intervention groups reported a slight improvement in self-perceived health in 1 of the 8 subscales of the SF-36. Combined in-person and web-based coaching may give a minor improvement in self-perceived health in women with obesity. However, the lack of impact on motivation, barriers, and self-efficacy warrants further research.

TRIAL REGISTRATION

ClinicalTrials.gov NCT05792657; https://clinicaltrials.gov/study/NCT05792657.

Deciphering the anti-obesity mechanisms of pharmabiotic probiotics through advanced multiomics analysis

Probiotics with "pharmabiotic" properties are increasingly recognized as effective tools for combating obesity by altering gut microbiota and reducing body fat. However, the molecular mechanisms underlying their anti-obesity effects remain largely unexplored due to the absence of a universal methodology. Herein, we developed a multiomics-based strategy to elucidate how probiotics reduce lipid production in adipocytes. Our initial investigation assessed the impact of probiotics at defined adipocyte differentiation stages. Leveraging these insights, we performed comprehensive multiomics analyses at key intervals to identify the suppression mechanisms of lipid formation. Lactobacillus reuteri, specifically, targets early differentiation stages, inhibits branched-chain amino acid catabolism, and reduces lipid accumulation in adipocytes by suppressing Krüppel-like factor 5. Concurrently, enhanced hypoxia-inducible factor 1 expression impedes adipogenesis by downregulating lipin-1 expression. This study not only demonstrates the effectiveness of our approach in revealing complex host-microbe interactions but also significantly advances probiotic therapeutic development, offering promising avenues for obesity management.

Association of oral health status with overweight and obesity in older adults aged ≥ 65 years- evidence from Chinese communities

OBJECTIVES

To evaluate the association of poor oral health conditions, such as caries, tooth loss, and tooth loss, with overweight and obesity in older adults and to complement evidence from the Chinese community to confirm this association. Additionally, we evaluated the sociodemographic characteristics, health status, and impact of health-related behavior on the BMI of older adults.

METHODS

This retrospective study involved health examination and follow-up data of 953 older adults from the Sichuan Province of China from 2021 to 2023. The caries status assessed by the Decayed, Missing, and Filled Teeth (DMFT) index, was used as the exposure factor, whereas body mass index (BMI) was used as the outcome indicator. The influence of confounding variables, namely the sociodemographic characteristics, health status, and oral health-related behavior, was controlled. BMI changes in older adults with different levels of oral health over 3 years were retrospectively followed up. Additionally, a Cox proportional hazard model was used to determine the association.

RESULTS

Overweight and obesity were prevalent in 29.3% and 20.4% of older adults with poor and good oral health status, respectively (P < 0.01). After controlling for the confounding factors, the Cox proportional hazards model demonstrated that the DMFT index was associated with overweight or obesity (BMI) (hazards ratio = 1.86, 95% confidence interval: 1.52-2.28). Overweight and obesity were less prevalent in older adults with fewer chronic diseases, higher frequency of physical exercise, and better oral health-related behaviors.

CONCLUSIONS

Oral health status is positively associated with overweight and obesity in older adults, particularly in older adults presenting with caries, missing teeth, and tooth loss as their primary symptoms.

Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis

The objective of this study is to quantitatively compare the weight loss effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adult patients with no diabetes and type 2 diabetes (T2D). PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and Embase have been used as data sources from database inception to January 6, 2024. A total of 137 trials, encompassing 310 treatment arms, 17 GLP-1RAs, and 56,683 patients, were included in the analysis. The included trials were divided into three groups based on the characteristics of the populations: nondiabetic overweight or obesity group (NDOOG), type 2 diabetes Caucasian group (T2DCG), and type 2 diabetes Asian group (T2DAG). The effects of covariates were further evaluated, patients with a higher baseline body weight tend to have better weight loss outcomes, and patients with a higher baseline glycated hemoglobin (HbA1c) tend to achieve better blood sugar control. Five mathematical models were subjected to longitudinal analysis. In terms of Δ body weight, retatrutide (12 mg qw) was the most effective treatment (mean difference = -26.56% [95% confidence interval: -43.89% to -3.01%]). Tirzepatide (15 mg qw) demonstrated good weight loss ability in all three ΔBW models, ΔBW-NDOOG (-22.76% [-26.45% to -18.50%]), ΔBW-T2DCG (-11.09% [-12.39% to -9.44%])), and ΔBW-T2DAG (-4.97% [-5.84% to -4.12%]). In the aspect of ΔHbA1c, tirzepatide (10 mg qw) and oral orforglipron (10 mg qd) were the most effective drug, respectively. GLP-1RAs demonstrated effective weight management in both nondiabetic and T2D populations. Retatrutide achieved the most pronounced weight reduction, followed by tirzepatide. GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.

Cognitive-Psychological Characteristics Influencing Weight Loss in Severe Obesity

Background/Objectives: Cognitive and psychological factors, such as eating disorder psychopathology, irrational food beliefs, and internalized weight stigma, have not been sufficiently explored in the context of obesity treatment. This study evaluated the role of these variables as predictors of weight loss in patients with severe obesity following a brief intensive cognitive-behavioral therapy for obesity (CBT-OB) program. Methods: A total of 400 patients (mean BMI: 41.9 kg/m2; mean age: 55.9 years) participated in a 21-day residential CBT-OB intervention, followed by a 12-month follow-up assessment. The Eating Disorder Examination Questionnaire, Weight Bias Internalization Scale, and Irrational Food Beliefs Scale were administered at admission and discharge. Body weight was also assessed at the 12-month follow-up. Results: Of the participants, 371 patients (92.2%) completed the intensive CBT-OB program, and 310 (81.1%) attended the follow-up. On average, completers achieved 9% weight loss at follow-up, accompanied by a significant reduction in binge-eating episodes. Cognitive factors, including lower baseline eating concern, higher baseline weight concern, and greater improvement in irrational beliefs (specifically self-deception about eating and weight control), significantly predicted weight loss at 12 months. However, internalized weight stigma did not predict weight loss in this cohort. Conclusions: This study underscores the importance of targeting specific cognitive factors in obesity treatment to enhance long-term outcomes. Addressing irrational food beliefs and promoting flexible dietary restraint may improve weight loss and maintenance in individuals with severe obesity. Further research is warranted to refine cognitive-behavioral interventions for personalized obesity management strategies.

Modulation of adiposity and adipocyte inflammation by methanol extracts of Alpinia calcarata leaf in high-fat-diet induced-obese mice: Involvement of COX-2 and PPAR-γ

Obesity is a worldwide problem linked to several lifestyle disorders like diabetes, hypertension, heart failure, dyslipidaemias, asthma, etc. Finding a cure for obesity and its consequences is essential. Alpinia calcarata, a plant from the Zingiberaceae family, has been reported for several medicinal properties. The current study aimed to check out the role of Alpinia calcarata leaf in decreasing adiposity and adipocyte inflammation in high-fat diet-induced obese mice and understand the molecular principles underlying this occurrence. An in-silico test was done with more abounded compounds of Alpinia calcarata with adiposity and inflammatory genes. Moreover, methanol extract of Alpinia calcarata leaves were utilized to confirm the in-silico data in-vivo. High-fat diet induced-obese mice were treated with the extract at 200mg/kg-body weight dose. Body weight, organ weight, fat accumulation, serum cholesterol, serum triglyceride level, and liver function test were monitored as function of obesity. Alteration in the expression of IL-6, COX-2, MCP-1, PPARγ, TNFα, and GLUT-4 at transcript level were also studied. Our in-vivo results indicated that the plant extracts significantly (p < 0.05) decreased weight and accumulation of abdominal fat which was followed by a considerable reduction in total cholesterol and triglyceride levels. In agreement with the in-silico data, the extract was capable to reduce the mRNA expression of IL-6, COX-2, MCP-1, PPARγ, TNFα, and GLUT-4 which were consistent with the biochemical evidence; demonstrating the extract's capacity to attenuate adiposity and adipocyte inflammation. Taking it all together, it is noteworthy to report this novel function of A. calcarata leaf in reducing adiposity and adipocyte inflammation.

Partially unraveling mechanistic underpinning and weight loss effects of time-restricted eating across diverse adult populations: A systematic review and meta-analyses of prospective studies

Time-restricted eating (TRE) is a promising and cost-effective dietary approach for weight management. This study aimed to evaluate the effects of TRE on weight loss in three adult populations using pre- and post-intervention analyses while also investigating its underlying mechanism. A systematic search was conducted across four databases (PubMed, Web of Science, Scopus, and the CENTRAL) up until January 28, 2024, specifically focusing on prospective studies that examined the efficacy of TRE in achieving weight loss. A random effects model was employed to conduct meta-analyses, while heterogeneity was assessed using the I2 statistic (PROSPERO: CRD42023439317). The study encompassed 36 selected studies involving 44 effect sizes and 914 participants. The effectiveness of the TRE was found to vary across health conditions, with modest weight loss observed in healthy individuals (pooled effect size -1.04 Kg, 95% CI: -1.42 to -0.65) and more significant weight reduction seen in participants with chronic diseases (pooled effect size -3.33 Kg, 95% CI: -5.05 to -1.62) and overweight/obesity (pooled effect size -4.21 Kg, 95% CI: -5.23 to -3.10). The observed decrease in body weight could be partially attributed to factors influencing energy balance, as evidenced by the significantly lower mean calorie intake at the end of the intervention (1694.71 kcal/day, 95% CI: 1498.57-1890.85) compared to the baseline intake (2000.64 kcal/day, 95% CI: 1830-2172.98), despite the absence of intentional efforts to restrict energy intake by the participants. These findings support the efficacy of this lifestyle intervention for weight loss maintenance and guide the development of its clinical guidelines.

The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates

Epigallocatechin gallate (EGCG) is the predominant bioactive catechin in green tea, and it has been ascribed a range of beneficial health effects. Current increases in obesity and non-alcoholic fatty liver disease (NAFLD) rates represent a persistent and burdensome threat to global public health. While many clinical studies have demonstrated that EGCG is associated with positive effects on various health parameters, including metabolic biomarkers, waist circumference, and body weight when consumed by individuals affected by obesity and NAFLD, there are also some reports suggesting that it may entail some degree of hepatotoxicity. The present review provides a comprehensive summary of the extant clinical findings pertaining to the safety and effectiveness of EGCG in managing obesity and NAFLD, with a particular focus on how treatment duration and dose level affect the bioactivity of this compound.

Mandibular trabecular bone pattern before and two years after medical or surgical obesity treatment in young Swedish women

OBJECTIVE

To investigate if changes in body mass index (BMI) result in changes of the mandibular trabecular bone structure.

MATERIALS AND METHODS

Females (18-35 years at baseline, mean BMI 42,3) were followed from before (n = 117) until two years (n = 66) after obesity treatment (medical or surgical). The mandibular bone trabeculation was classified as sparse, dense, or mixed on intraoral radiographs (Lindh's index). A digitized method (Jaw-X) assessed the size and intensities of intertrabecular spaces. The main predictor variable was BMI reduction over the period.

RESULTS

Before treatment, the group with a high BMI (≥ 45) had a significantly denser bone than those with a lower BMI (p = 0.035). Two years after treatment, fewer were classified with sparse bone (Lindh's index p = 0.001, Jaw-X p = 0.009). The physical activity increased with fewer having a sedentary lifestyle (40% before, 17% after treatment). The association between BMI reduction and the difference in Jaw-X was significant in regression models and not influenced by obesity treatment method but by baseline factors as age, trabecular bone pattern and level of ionized calcium.

CONCLUSIONS

Before obesity treatment, high BMI was associated with dense bone trabeculation in the jaw. The group with sparse bone had decreased at follow-up. The association between BMI reduction and bone trabeculation was influenced by individual and medical factors.

CLINICAL RELEVANCE

Bone trabeculation in the mandible was maintained during the first years after obesity treatment but new health habits should be encouraged, and patients need to be monitored and followed up further.

Efficacy of intermittent fasting on improving liver function in individuals with metabolic disorders: a systematic review and meta-analysis

BACKGROUND

Intermittent fasting (IF) can be an effective dietary therapy for weight loss and improving cardiometabolic health. However, there is scant evidence regarding the role of IF on indicators of liver function, particularly in adults with metabolic disorders. Therefore, we performed a systematic review and meta-analysis to investigate the effects of IF on liver function in adults with metabolic disorders.

METHODS

Three primary electronic databases including PubMed, Web of Science, and Scopus, were searched from inception to September 2024 to identify original studies that used IF interventions with or without control groups in adults with metabolic disorders. Inclusion criteria were (1) studies of human participants with metabolic diseases, (2) interventions that evaluated the effects of IF, (3) with or without a control group, and (4) measured liver fat, liver steatosis, liver fibrosis, or liver enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as primary outcomes. Standardized mean differences (SMD) and 95% confidence intervals were calculated using random effects models. Heterogeneity was assessed using the Cochran's Q statistic and I-squared statistic (I2). Publication bias was assessed using the visual inspection of funnel plots and Egger's tests. The risk of bias was assessed using the PEDro scale and the NIH quality assessment tool.

RESULTS

A total 21 studies involving 1,226 participants with metabolic disorders were included in the meta-analysis. Overall, IF effectively decreased liver fat with a large effect size [SMD: -1.22 (95% CI: -1.63 to -0.80), p = 0.001], liver steatosis with a medium effect size [SMD: -0.73 (95% CI: -1.12 to -0.35), p = 0.001], ALT with a small effect size [SMD: -0.44 (95% CI: -0.58 to -0.30), p = 0.001], and AST with a small effect size [SMD: -0.30 (95% CI: -0.49 to -0.11), p = 0.001], but not liver fibrosis [SMD: -0.28 (95% CI: -0.59 to 0.02), p = 0.07]. Subgroup analyses showed that IF decreased liver fat and ALT significantly, independent of IF mode, participant age, health status, weight status, and intervention duration. IF significantly decreased liver fibrosis in those with obesity; and decreased AST following 5:2 diets, in middle-aged adults, adults with obesity, and regardless of health status or intervention duration.

CONCLUSIONS

IF seems to be an effective dietary therapy for improving liver function in adults with metabolic disorders, and many of liver function-related benefits occur regardless of IF mode, intervention duration, or participant health status.

LIMITATIONS

Significant heterogeneity, small numbers of studies and inclusion of non-randomized trials or single-group pre-post trials were the main limitation of our meta-analysis. Further randomized clinical trials are needed to elucidate the effects of IF on liver function in adults with metabolic disorders.

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Dyslipidemia is a major risk factor for cardiovascular disease, and its impact may be exacerbated when accompanied by metabolic dysfunction-associated steatotic liver disease (MASLD). The simultaneous management of these conditions poses multiple challenges for healthcare providers. Insulin resistance has been implicated in the pathogenesis of both dyslipidemia and MASLD, necessitating a holistic approach to managing dyslipidemia, glucose levels, body weight, and MASLD. This review explores the intricate pathophysiological relationship between MASLD and dyslipidemia. It also examines current guidance regarding the use of lipid-lowering agents (including statins, ezetimibe, fibrates, omega-3 polyunsaturated fatty acids, and proprotein convertase subtilisin/kexin type 9 inhibitors) as well as glucose-lowering medications (such as pioglitazone, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter 2 inhibitors) in patients with MASLD, with or without metabolic dysfunction-associated steatohepatitis (MASH), and dyslipidemia. Additionally, the review addresses the potential of emerging drugs to concurrently target both MASLD/MASH and dyslipidemia. Our hope is that a deeper understanding of the mechanisms underlying MASLD and dyslipidemia may assist clinicians in the management of these complex cases.

[Pharmacological treatment of obesity. Current situation and new treatments]

The high incidence of obesity in our environment, the progressive and recurrent nature of this disease makes it necessary to know and use all the possibilities of prevention and treatment. When a person suffers from obesity we must offer a treatment plan with specific objectives that will include healthy eating, physical activity and, if necessary, treatment with medication or even surgery. At present in Spain, there are 3 medications available: New molecules will soon be marketed that will expand the treatment possibilities, which will also be reviewed in this article.

Lipid profiling identifies modifiable signatures of cardiometabolic risk in children and adolescents with obesity

Pediatric obesity is a progressive, chronic disease that can lead to serious cardiometabolic complications. Here we investigated the peripheral lipidome in 958 children and adolescents with overweight or obesity and 373 with normal weight, in a cross-sectional study. We also implemented a family-based, personalized program to assess the effects of obesity management on 186 children and adolescents in a clinical setting. Using mass spectrometry-based lipidomics, we report an increase in ceramides, alongside a decrease in lysophospholipids and omega-3 fatty acids with obesity metabolism. Ceramides, phosphatidylethanolamines and phosphatidylinositols were associated with insulin resistance and cardiometabolic risk, whereas sphingomyelins showed inverse associations. Additionally, a panel of three lipids predicted hepatic steatosis as effectively as liver enzymes. Lipids partially mediated the association between obesity and cardiometabolic traits. The nonpharmacological management reduced levels of ceramides, phospholipids and triglycerides, indicating that lowering the degree of obesity could partially restore a healthy lipid profile in children and adolescents.

Semaglutide outperforms insulin in restoring neutrophil function against implant-related infection in diabetic and obese mice: experimental research

BACKGROUND

Bone and joint infections (BJI) are a significant complication after arthroplasty and fracture fixation, particularly challenging in patients with type 2 diabetes mellitus (T2DM) and obesity. Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has shown efficacy in managing T2DM and obesity. However, its impact on BJI risk and neutrophil function remains unclear. To investigate whether preoperative semaglutide treatment (1) reduces the risk of BJI in diabetic and obese mice undergoing intra-articular implants, and (2) outperforms insulin in restoring neutrophil function to mitigate implant-related infection.

METHODS

A C57BL/6 mouse model of T2DM/obesity was induced using a high-fat diet (HFD) for 12 weeks. Mice received preoperative insulin or semaglutide therapy for 1-28 days. BJI risk was assessed using an intra-articular-implant model challenged with Staphylococcus aureus or Escherichia coli . The neutrophil function was evaluated through bactericidal activity, superoxide production, and migration ability.

RESULTS

Semaglutide treatment led to a significant and sustained reduction in body weight and improved glucose tolerance in HFD mice. Both insulin and semaglutide therapies significantly reduced BJI risk, with semaglutide showing a more pronounced effect over time. Semaglutide therapy also enhanced neutrophil bactericidal activity, superoxide production, and migration ability compared to insulin therapy.

CONCLUSIONS

Preoperative semaglutide treatment effectively reduces BJI risk and improves neutrophil function in diabetic and obese mouse models. These findings suggest that semaglutide may be a promising pharmacological intervention to mitigate infection risk in orthopedic patients with T2DM or obesity.

Bariatric surgery for treatment of morbid obesity in adults

Morbid obesity requires active intervention, with treatment options including lifestyle modification, pharmacotherapy, and surgery. As the prevalence of obesity continues to rise in Korea, it is crucial for specialists and general practitioners to have a comprehensive understanding of obesity and its management. Bariatric surgery is the most effective treatment modality for obesity, leading to significant weight loss and metabolic benefits. It involves surgical alterations of normal anatomical structures to improve overall health. Therefore, selecting the appropriate procedure based on the individual characteristics of patients is crucial. This review highlights the two most commonly performed bariatric procedures worldwide, including in Korea: sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB). Furthermore, it provides a comprehensive overview of the surgical techniques involved in SG and RYGB, addresses potential complications, and presents findings from key studies on the weight loss and metabolic outcomes of these surgeries. Additionally, to support clinical application, the review provides outcome data for these procedures based on studies conducted in Korean populations. In addition to SG and RYGB, this review briefly introduces other surgical and endoscopic options, as well as pharmacological treatments that are currently available or may become viable options in the near future.

Tirzepatide's role in targeting adipose tissue macrophages to reduce obesity-related inflammation and improve insulin resistance

BACKGROUND

Obesity and type 2 diabetes mellitus (T2DM) are significant global health challenges, with adipose tissue inflammation being a pivotal contributor to metabolic dysfunction. The involvement of adipose tissue macrophages (ATMs) in obesity-associated inflammation is well recognized, yet the therapeutic strategies specifically targeting ATM-mediated inflammation remain limited.

OBJECTIVE

This study aims to explore the effects of tirzepatide, a novel dual GLP-1 and GIP receptor agonist, on ATMs, adipose tissue inflammation, and insulin resistance in the context of obesity.

METHODS

Obese mouse models were established through high-fat diet feeding and subsequently treated with tirzepatide at a dose of 1.2 mg/kg twice weekly for 12 weeks. The study assessed the impact on ATM phenotype, inflammatory markers, and key metabolic indicators.

RESULTS

Tirzepatide treatment significantly mitigated the infiltration of pro-inflammatory M1 ATMs within adipose tissue and concurrently reduced levels of inflammatory cytokines, thereby enhancing insulin sensitivity. Tirzepatide demonstrated therapeutic efficacy through its modulation of the ERK signaling pathway and promotion of M1-type macrophage apoptosis.

CONCLUSION

Tirzepatide's potential as a therapeutic strategy for addressing metabolic diseases associated with obesity and T2DM by targeting ATM activity and mitigating obesity-associated inflammation.

The Greater the Number of Altered Eating Behaviors in Obesity, the More Severe the Psychopathology

Background: Altered eating behaviors (AEBs) are not only associated with eating disorders but also play a role in obesity. This study assessed AEBs in individuals with obesity and their association with general and eating psychopathology, using the "Eating Behaviors Assessment for Obesity" (EBA-O). The hypothesis posited that a higher frequency of pathological eating behaviors would correlate with more severe psychopathology. Methods: Participants seeking weight loss treatment answered the EBA-O and other measures of eating and general psychopathology. The analysis employed MANOVA to estimate psychopathological variance based on AEBs and a cluster analysis to identify patient clusters by AEB type and number. Results: Out of the 244 participants, approximately two-thirds reported clinically relevant AEBs, with almost half exhibiting more than two AEBs. Predominant AEBs included sweet eating, binge eating, and hyperphagia. A significant impact of the numbers of AEBs on both eating and general psychopathology severity (p < 0.001; η2 = 0.167) was evident. Three clusters emerged, with Cluster 3 showing the highest AEB frequency and greater psychopathological impairment. Conclusions: The present findings confirm the correlation between the frequency of AEBs and the severity of general and eating psychopathology in individuals with obesity. AEBs deserve clinical attention, and their screening might aid their clinical characterization and foster more tailored treatments.

EPA guidance on lifestyle interventions for adults with severe mental illness: A meta-review of the evidence

There is growing interest in lifestyle interventions as stand-alone and add-on therapies in mental health care due to their potential benefits for both physical and mental health outcomes. We evaluated lifestyle interventions focusing on physical activity, diet, and sleep in adults with severe mental illness (SMI) and the evidence for their effectiveness. To this end, we conducted a meta-review and searched major electronic databases for articles published prior to 09/2022 and updated our search in 03/2024. We identified 89 relevant systematic reviews and assessed their quality using the SIGN checklist. Based on the findings of our meta-review and on clinical expertise of the authors, we formulated seven recommendations. In brief, evidence supports the application of lifestyle interventions that combine behavioural change techniques, dietary modification, and physical activity to reduce weight and improve cardiovascular health parameters in adults with SMI. Furthermore, physical activity should be used as an adjunct treatment to improve mental health in adults with SMI, including psychotic symptoms and cognition in adults with schizophrenia or depressive symptoms in adults with major depression. To ameliorate sleep quality, cognitive behavioural informed interventions can be considered. Additionally, we provide an overview of key gaps in the current literature. Future studies should integrate both mental and physical health outcomes to reflect the multi-faceted benefits of lifestyle interventions. Moreover, our meta-review highlighted a relative dearth of evidence relating to interventions in adults with bipolar disorder and to nutritional and sleep interventions. Future research could help establish lifestyle interventions as a core component of mental health care.

A gut microbial metabolite cocktail fights against obesity through modulating the gut microbiota and hepatic leptin signaling

BACKGROUND

Excessive body weight and obesity elevate the risk of chronic non-communicable diseases. The judicious application of the gut microbiome, encompassing both microorganisms and their derived compounds, holds considerable promise in the treatment of obesity.

RESULTS

In this study, we showed that a cocktail of gut microbiota-derived metabolites, comprising indole 3-propionic acid (IPA), sodium butyrate (SB) and valeric acid (VA), alleviated various symptoms of obesity in both male and female mice subjected to a high-fat diet (HFD). The 16S ribosomal RNA (rRNA) sequencing revealed that administering the cocktail via oral gavage retained the gut microbiota composition in obese mice. Fecal microbiota transplantation using cocktail-treated mice as donors mitigated the obesity phenotype of HFD-fed mice. Transcriptomic sequencing analysis showed that the cocktail preserved the gene expression profile of hepatic tissues in obese mice, especially up-regulated the expression level of leptin receptor. Gene delivery via in vivo fluid dynamics further validated that the anti-obesity efficacy of the cocktail was dependent on leptin signaling at least partly. The cocktail also inhibited the expression of appetite stimulators in hypothalamus. Together, the metabolite cocktail combated adiposity by retaining the gut microbiota configuration and activating the hepatic leptin signaling pathway.

CONCLUSIONS

Our findings provide a sophisticated regulatory network between the gut microbiome and host, and highlight a cocktail of gut microbiota-derived metabolites, including IPA, SB, and VA, might be a prospective intervention for anti-obesity in a preclinical setting. © 2024 Society of Chemical Industry.

Research trends of traditional Chinese non-pharmacological therapy in the management of overweight and obesity from 2004 to 2023: A bibliometric study

OBJECTIVE

Traditional Chinese non-pharmacological therapy has gained popularity in the management of overweight and obesity. This study aims to reveal trends and hotspots of global research on traditional Chinese non-pharmacological therapies for overweight and obesity.

METHODS

Publications on traditional Chinese non-pharmacological therapies for overweight and obesity between 2004 and 2023 were searched from the Web of Science Core Collection. Bibliometric analyses and visualization were performed using VOSviewer, CiteSpace, and R software.

RESULTS

A total of 566 publications from 246 journals were included in this study. Annual number of publications and cited times in the field were generally increasing. China contributed the most publications, followed by the United States and Republic of Korea, and Chengdu University of Traditional Chinese Medicine from China had the highest number of publications among institutions. Stener-Victorin E was not only the most productive author but also, along with Cabioglu MT, the most cited authors. Evidence-Based Complementary and Alternative Medicine was both the largest source journal and the most cited journal. The highly cited references mainly consists of clinical trials, narrative reviews and systematic reviews focusing on acupuncture therapy. Keywords analysis indicated that acupuncture therapy and traditional Chinese exercise constituted the main components of traditional Chinese non-pharmacological therapy in weight management.

CONCLUSIONS

This study revealed a growing interest in traditional Chinese non-pharmacological therapies for managing overweight and obesity, with acupuncture therapies and traditional Chinese exercises as the main research focuses. This study offers insights into traditional Chinese non-pharmacological therapies in weight management, and may benefit further research.

Postingestive reward acts through behavioral reinforcement and is conserved in obesity and after bariatric surgery

Postingestive nutrient stimulation conditions food preferences through striatal dopamine and may be associated with blunted brain responses in obesity. In a cross-sectional study, we tested flavor-nutrient conditioning (FNC) with maltodextrin-enriched yogurt, with maltodextrin previously optimized for concentration and dextrose equivalents (n = 57), and to mask texture cues (n = 102). After conditioning, healthy volunteers (n = 52) increased preference for maltodextrin-paired (+102 kcal, CS+), relative to control (+1.8 kcal, CS-) flavors, as assessed according to intake, but not pleasantness. In a clinical study (n = 61), behavioral conditioning without effects on pleasantness was confirmed across pre-bariatric candidates with obesity, weight-stable post-surgery patients, and healthy controls, without significant differences between groups. Striatal dopamine D2-like receptor (DD2lR) availability, assessed with [123I]IBZM SPECT, was reduced in the obesity group and strongly correlated with conditioning strength and a measure of restrained eating in patients with gastric bypass. These results show that postingestive nutrient stimulation influences human food choices through behavioral reinforcement, and is conserved in obesity and after bariatric surgery. Trial Registration: ISRCTN17965026: Dopaminergic neurotransmission in dietary learning and obesity.

Histological Changes in Skin and Subcutaneous Cellular Tissue in Patients with Massive Weight Loss After Bariatric Surgery

INTRODUCTION

Morbid obesity is a public health problem with high social and economic impact. Due to failure in its treatment with traditional weight loss strategies, surgical interventions are usually required, which give rise to massive weight loss. Until now, the studies made are inconclusive regarding the histological changes in the skin caused by massive weight loss, which may later generate post-surgical complications. Therefore, the objective of this study is to evaluate the cutaneous histological changes before and after bariatric surgery.

MATERIAL AND METHODS

Two skin biopsies were taken from nine different patients who underwent bariatric surgery. The first biopsy was taken before the surgical intervention, and the second biopsy was taken a year after the surgery and massive weight loss. Histological analysis was performed using haematoxylin & eosin staining, Weigert's Resorcin-Fuchsin, and Masson's trichrome stain to analyse the percentage of collagen fibres, percentage of fibrosis, percentage of vascularity, vascular layer involvement and adipocyte population. The differences between the biopsies were evaluated with the Student's T test and Mann-Whitney U test, with a p-value of <0.05.

RESULTS

Biopsies from post-bariatric patients with MWL showed an increase in fibrosis percentage, and a decrease in collagen fibres, elastic fibres of the dermis, adipocyte population, as well as reduced vascular proliferation.

CONCLUSION

MWL after bariatric surgery gives rise to changes in the skin and subcutaneous cellular tissue. Skin shows an increased fibrosis percentage after massive weight loss. Elastic and collagen fibres become disorganized after massive weight loss. Vascular proliferation is decreased after massive weight loss.

LEVEL OF EVIDENCE IV

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Weight Trends After Spinal Cord Stimulation Therapy for Chronic Pain

OBJECTIVES

Spinal cord stimulation (SCS) therapy is an effective treatment for chronic pain, particularly in conditions such as postlaminectomy syndrome and complex regional pain syndrome (CRPS). Rare case reports described significant weight loss in patients who underwent dorsal column SCS therapy for chronic pain. Recently, neuromodulation for obesity has become a novel field for research. We aimed to investigate weight trends among patients treated with SCS for chronic pain.

MATERIALS AND METHODS

We conducted a retrospective chart review in 342 patients treated with SCS or dorsal root ganglion stimulators at our institution between 2010 and 2023. Patients had their weight recorded before SCS implantation and at least once within 12 months after surgery. We also conducted interviews with 28 patients who experienced significant weight loss or had revision procedures owing to weight loss.

RESULTS

We found that 105 of 342 patients (30.7%) experienced weight loss of ≥5% within a year of implantation, and 32 of 105 (30.5%, 9.4% of all patients) experienced weight loss of ≥ 10%. A multivariate regression analysis revealed a modest increase in the likelihood of weight loss among patients with CRPS (odds ratio [OR] = 1.17, 95% CI [1.04, 1.30], p = 0.007) and in those who achieved pain relief after implantation (OR = 1.22, 95% CI [1.05,1.40], p = 0.008). Of the 28 patients with significant weight loss who were interviewed, 12 (43%) could not explain the reasons for their weight loss, whereas eight (29%) reported decreased appetite. Leads placed at higher thoracic levels were associated with increased rates of weight loss (37.2% at T6-T8 and 22.3% at T8-T10; p = 0.038).

CONCLUSIONS

Our findings suggest that SCS therapy may affect weight in patients with chronic pain. Further studies are needed to investigate the potential role of SCS in weight modulation.

Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps

INTRODUCTION

Trials of GLP-1 (glucagon-like peptide-1) medicines have changed the paradigm of obesity treatment. Diversity in trial participation is imperative considering that obesity disproportionately impacts marginalised populations worldwide. We performed a systematic review and meta-analyses to evaluate the representation of racialised and ethnically diverse populations in randomised controlled trials (RCTs) of GLP-1 medicines for obesity.

METHODS

We searched PubMed/Embase/ClinicalTrials.gov. Prevalence of each racial/ethnic group was compared in relation to the USA, Canada, the UK, Brazil and South Africa. The geographical locations of the trial sites were extracted.

RESULTS

27 RCTs were identified (n=21 547 participants). Meta-analyses of prevalence demonstrated the vast predominance of white/Caucasians (79%) with smaller proportion of blacks (9%), Asians (13%), Indigenous (2%) and Hispanics (22%). The gaps in representation were evidenced by the significantly under-represented proportion of non-white individuals in these RCTs as compared with the prevalence of non-white individuals in the general population of the USA (-23%, p=0.002) and Canada (-34%, p<0.0001), reaching an alarming gap of -58% in relation to Brazil and striking under-representation of -68% as compared with South Africa. Similar discrepancies in proportions of blacks, Asians and Indigenous peoples as compared with reference nations were found. Moreover, the trial sites (n=1859) were predominately located in high-income countries (84.2%), in sharp contrast to the global prevalence of obesity that is predominantly in low-income and middle-income countries.

CONCLUSION

There are discrepancies in representation of racialised and ethnically diverse populations in obesity trials as compared with multiethnic populations worldwide. These data highlight the need for broader reform in the research process in order to ultimately address health inequities.

Exercise as a Therapeutic Strategy for Obesity: Central and Peripheral Mechanisms

Obesity is a complex, multifactorial condition involving excessive fat accumulation due to an imbalance between energy intake and expenditure, with its global prevalence steadily rising. This condition significantly increases the risk of chronic diseases, including sarcopenia, type 2 diabetes, and cardiovascular diseases, highlighting the need for effective interventions. Exercise has emerged as a potent non-pharmacological approach to combat obesity, targeting both central and peripheral mechanisms that regulate metabolism, energy expenditure, and neurological functions. In the central nervous system, exercise influences appetite, mood, and cognitive functions by modulating the reward system and regulating appetite-controlling hormones to manage energy intake. Concurrently, exercise promotes thermogenesis in adipose tissue and regulates endocrine path-ways and key metabolic organs, such as skeletal muscle and the liver, to enhance fat oxidation and support energy balance. Despite advances in understanding exercise's role in obesity, the precise interaction between the neurobiological and peripheral metabolic pathways remains underexplored, particularly in public health strategies. A better understanding of these interactions could inform more comprehensive obesity management approaches by addressing both central nervous system influences on behavior and peripheral metabolic regulation. This review synthesizes recent insights into these roles, highlighting potential therapeutic strategies targeting both systems for more effective obesity interventions.

Assessing the effectiveness of health belief model-based educational interventions on weight control intentions among Malaysians

Obesity and overweight are major health concerns, with a 19.7% prevalence among Malaysian adults, as reported in the 2019 National Health and Morbidity Survey. This study assessed the effectiveness of an educational intervention on weight control intention using the Health Belief Model (HBM). A quasi-experimental design was employed, involving 140 participants equally divided into an intervention group (IG) and a control group (CG). Post-intervention, the IG showed significant improvement in perceived self-efficacy in dieting (mean score 3.96 ± 0.85) compared to the CG (3.76 ± 0.86, p = 0.003). Perceived self-efficacy in exercise also increased in the IG (4.12 ± 0.52) compared to the CG (3.51 ± 0.94, p < 0.001). While behavioral intention scores improved in the IG (4.00 ± 0.59), the difference was not significant (p = 0.300). This study highlights that educational interventions using HBM can effectively improve self-efficacy and influence weight control behaviors.

The First Triple Agonist for Antiobesity: Retatrutide

The prevalence of individuals with overweight and obesity has increased by 18% since 1990 and it is projected that by 2030, nearly 50% of US adults will have obesity. Lifestyle modifications, such as diet and exercise, typically lead to approximately 3-5% weight loss, whereas 5-15% weight loss is necessary to significantly impact obesity-associated comorbidities and improve overall health outcomes. In addition to lifestyle modifications, pharmacotherapy has been utilized as an adjunctive treatment to increase weight loss and improve health outcomes. The Food and Drug Administration has currently approved 6 drugs to treat overweight and obesity, with the recently approved drugs surging in popularity after demonstrating superior weight loss outcomes. Additionally, a number of agents are in the pipeline, offering promise of unprecedented degrees of weight loss. One such drug is retatrutide, which is a triple agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor, and glucagon receptor. Phase 1 and 2 clinical trials have demonstrated the safety, tolerability, and pharmacokinetics of retatrutide in patients with obesity and/or type 2 diabetes. The pharmacokinetics of retatrutide were dose proportional and its mean half-life of approximately 6 days supported a once-weekly dosing. The safety profile was similar to GLP-1R agonists and glucose-dependent insulinotropic polypeptide receptor/GLP-1R co-agonists, with gastrointestinal disorders being the most common adverse effects reported. Each trial demonstrated greater weight loss with retatrutide treatment in comparison to placebo, with greatest efficacy at higher doses. Overall, these clinical trials have demonstrated the superior efficacy of retatrutide as a weight loss medication in patients with overweight and obesity.

Features and behaviours for weight loss in the Chilean cohort with obesity from the ACTION study

In Latin America, obesity rates are among the highest in the world. Currently, people with obesity (PWO) receive suboptimal care due to several challenges and barriers. The international ACTION-IO study aimed to identify perceptions, attitudes and behaviours of PWO and healthcare providers (HCP), and to assess potential barriers to effective obesity care. The aim of this subanalysis of the Chilean cohort was to compare their characteristics, perceptions, attitudes and behaviours according to the percentage of weight loss (lower weight loss [LWL; ≤10%] or higher weight loss [HWL; >10%] of basal weight). The ACTION-IO survey was completed by 1000 Chilean PWO and 200 HCPs. Mean age of PWO was 38 years (range 18-75); 62% were female. The majority had class I obesity. HWL subgroup represented 17.2% of all Chilean subset. Specific characteristics of patients with HWL were identified (higher educational level, lower proportion of class III obesity, preference for consulting obesity specialists, considering conversations with HCP as very helpful). HWL patients reported higher rates of favourable outcomes following HCP advice and a higher probability of attending scheduled follow-up visits. Certain demographic and behavioural variables (educational level, consultation to obesity specialists, adherence to HCP advice, follow-up scheduled visits and becoming aware of the obesity state) may identify PWO with a higher probability of a greater weight loss.

Elevated Interleukin-6 Is Associated with Successful Weight Loss 3 Months Postlaparoscopic Sleeve Gastrectomy

PURPOSE

Bariatric surgery poses an ever-increasing importance in the effective and long-lasting treatment of obesity, a condition strongly associated with inflammation and increased risk of other diseases and health problems. In obesity-related inflammation, maintaining a balance between pro-inflammatory and anti-inflammatory cytokines is crucial. In this study, we examined early effects of laparoscopic sleeve gastrectomy (LSG) on inflammatory and anti-inflammatory cytokines in obese patients, and assessed their effect on postoperative weight loss.

MATERIALS AND METHODS

This prospective cohort study was conducted from September 2022 till June 2023. Fifty obese adults were enrolled for LSG. All patients underwent assessments of body measurements, as well as levels of interleukin-6 (IL-6), interleukin-10 (IL-10), and TNF-alpha at baseline and 3 months postsurgery. We developed a decision tree model to predict the success of weight loss.

RESULTS

At 3 months postsurgery, patients lost 18.9 ± 6.9 kg of excess body weight. A significant decrease was observed for IL-10 (p < 0.0001), simultaneously with a significant increase in IL-6 (p < 0.0001). We found that high IL-6 (> 1.169 pg/mL) levels could contribute to an effective weight loss among patients with a baseline BMI less than 47.46 kg/m2.

CONCLUSION

Study revealed that 3 months after bariatric surgery, inflammation persists, and its markers significantly influence postoperative weight loss, as indicated by BMI range. Distinct behaviors of IL-10 and IL-6 in relation to obesity underline the necessity of considering individual cytokine profiles when evaluating bariatric surgery outcomes.